Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

[1]  S. Armstrong,et al.  Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia. , 2022, Cancer discovery.

[2]  B. Ebert,et al.  Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 , 2022, Leukemia.

[3]  B. Falini,et al.  Current status and future perspectives in targeted therapy of NPM1-mutated AML , 2022, Leukemia.

[4]  S. Grant,et al.  Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives , 2022, Blood reviews.

[5]  H. Schrezenmeier,et al.  Enhanced stimulation of antigen‐specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti‐programmed death 1 antibody , 2022, British journal of haematology.

[6]  N. Pemmaraju,et al.  Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) , 2022, Expert opinion on pharmacotherapy.

[7]  Y. Qi,et al.  Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) , 2022, Blood cancer journal.

[8]  S. Armstrong,et al.  Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold? , 2022, Cancer journal.

[9]  M. Andreeff,et al.  Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML. , 2021, Blood.

[10]  M. Andreeff,et al.  Therapeutic implications of menin inhibition in acute leukemias , 2021, Leukemia.

[11]  D. Lin,et al.  Super-enhancer-mediated core regulatory circuitry in human cancer , 2021, Computational and structural biotechnology journal.

[12]  F. Loganzo,et al.  Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia , 2020, Clinical Cancer Research.

[13]  L. Bullinger,et al.  Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. , 2020, Blood.

[14]  B. Falini,et al.  NPM1-mutated acute myeloid leukemia: from bench to bedside. , 2020, Blood.

[15]  S. Armstrong,et al.  Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.

[16]  C. Bloomfield,et al.  Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years , 2020, Leukemia.

[17]  M. Konopleva,et al.  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.

[18]  S. Armstrong,et al.  Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia , 2020, Science.

[19]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[20]  Jie Jin,et al.  Venetoclax and arsenic showed synergistic anti‐leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation , 2020, American journal of hematology.

[21]  O. Abdel-Wahab,et al.  Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. , 2019, The Journal of clinical investigation.

[22]  C. Bloomfield,et al.  Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.

[23]  F. Lussana,et al.  Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia , 2019, Cancers.

[24]  Michael R. Green,et al.  RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1. , 2019, Blood.

[25]  R. Levine,et al.  Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis , 2019, Leukemia.

[26]  P. Sharma,et al.  Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.

[27]  C. Plass,et al.  Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation , 2018, Leukemia.

[28]  E. Kjeldsen,et al.  Systematic evaluation of signal-to-noise ratio in variant detection from single cell genome multiple displacement amplification and exome sequencing , 2018, BMC Genomics.

[29]  Charles Y. Lin,et al.  Mutant NPM1 Maintains the Leukemic State through HOX Expression. , 2018, Cancer cell.

[30]  B. Porse,et al.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates , 2018, The Journal of clinical investigation.

[31]  S. Gill,et al.  Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse , 2018, Leukemia & lymphoma.

[32]  Darren L. Smith,et al.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.

[33]  R. Garzon,et al.  A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. , 2017, Blood.

[34]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[35]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[36]  J. Cayuela,et al.  Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Krämer,et al.  Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia , 2016, Blood Cancer Journal.

[38]  A. Look,et al.  KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells , 2016, Leukemia.

[39]  Richard A Young,et al.  Models of human core transcriptional regulatory circuitries , 2016, Genome research.

[40]  J. Byrd,et al.  Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies , 2015, Leukemia.

[41]  B. Falini,et al.  Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[42]  B. Falini,et al.  Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. , 2015, Blood.

[43]  E. Estey,et al.  Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Thomas D. Wu,et al.  A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.

[45]  N. Gray,et al.  Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies , 2014, Leukemia.

[46]  Diwakar,et al.  SUPPLEMENTARY INFORMATION for Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes , 2014 .

[47]  J. Qi,et al.  Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells , 2014, Molecular Cancer Therapeutics.

[48]  Ming Yu,et al.  Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation , 2013, Genes & development.

[49]  Guy Sauvageau,et al.  Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene‐Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia , 2013, Stem cells.

[50]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[51]  O. Dovey,et al.  A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice , 2013, Leukemia.

[52]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[53]  J. Hess,et al.  The pathogenesis of mixed-lineage leukemia. , 2012, Annual review of pathology.

[54]  M. Caligiuri,et al.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Pileri,et al.  Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications , 2009, Leukemia.

[56]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[57]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[58]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[59]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[60]  S. Armstrong,et al.  Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. , 2016, Cancer discovery.